Reaction
Systemic Scleroderma reporting signals
As of the last recalculation, Systemic Scleroderma appears in 710 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is SELEXIPAG (PRR 49.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Selexipag | 41 | 49.3 | 49.4 |
| Nintedanib | 45 | 44.8 | 44.9 |
| Sildenafil Powder, | 38 | 33.0 | 33.0 |
| Macitentan | 68 | 31.7 | 31.8 |
| Pemetrexed | 20 | 28.1 | 28.1 |
| Bosentan | 42 | 25.9 | 25.9 |
| Docetaxel Anhydrous | 50 | 23.3 | 23.3 |
| Docetaxel | 50 | 23.3 | 23.3 |
| Sildenafil | 43 | 23.1 | 23.1 |
| Tadalafil | 69 | 22.3 | 22.3 |
| Pemetrexed Disodium | 23 | 18.3 | 18.3 |
| Riociguat | 17 | 15.6 | 15.6 |
| Fluorouracil Cream, 0.5% | 35 | 14.1 | 14.1 |
| Fluorouracil | 35 | 13.9 | 13.9 |
| Pertuzumab | 12 | 13.1 | 13.2 |
| Blinatumomab | 4 | 11.3 | 11.3 |
| Treprostinil | 36 | 8.8 | 8.8 |
| Durvalumab | 6 | 8.7 | 8.7 |
| Ambrisentan | 32 | 7.8 | 7.8 |
| Osimertinib | 8 | 7.4 | 7.4 |